Omega-3-Polyunsaturated Fatty-Acids (N3-Pufa) In Patients With Severe Chronic Heart Failure
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Omega-3-Polyunsaturated Fatty-Acids (N3-Pufa) In Patients With Severe Chronic Heart Failure:Effects On Endothelial Function, Left Ventricular Remodelling, Natriuretic Peptide Levels, And Exercise Capacity
Study Start Date
Primary Completion Date
Study Completion Date
Resource links provided by the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Chronic heart failure of non-ischemic origin
Age ≥18 years
NYHA functional class III-IV
LVEF < 35 %
Optimized heart failure therapy
plasma NT-BNP >2000pg/ml
Current treatment with Omacor or other fish oil products
Known hypersensitivity to the study drug
Uncorrected significant valvular heart disease
Heart failure due to congenital heart disease
Alcoholic heart disease
Continuous i.v. therapy for heart failure
Mechanical assist device
Life expectancy <1 year due to non-cardiac causes
Inability to perform bicycle testing
Women of childbearing potential not practicing a save contraception method
Current participation in another intervention study
Participation in another study with an intervention within the last 3 months.